NCT00434356终止2 期
A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 46
- 主要终点
- Best Response
研究概览
简要总结
This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not previously received chemotherapy for locally recurrent or metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Histologically or cytologically confirmed adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease
- •Age ≥ 18 years
- •Adequate left ventricular function at study entry, defined as an Left Ventricular Ejection Fraction (LVEF) > 50% by either Multi Gated Acquisition(MUGA) scan or Electrocardiogram (ECHO)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Ability and willingness to comply with study and follow-up procedures
排除标准
- •Unknown HER2 status or known HER2-positive status
- •Prior chemotherapy for locally recurrent or metastatic disease
- •Prior hormonal therapy within 2 weeks prior to Day 1
- •Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to Day 1
- •Prior adjuvant or neoadjuvant non-taxane chemotherapy within 6 months prior to Day 1
- •For patients who have received recent radiotherapy, ongoing Grade ≥ 3 acute toxicity
- •Patients with brain metastasis on full dose anticoagulation therapy
- •Life expectancy of < 12 weeks
- •Current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study
- •Inadequate organ function within 28 days prior to Day 1
- •Untreated abnormal thyroid function tests
- •Uncontrolled serious medical or psychiatric illness
- •Active infection requiring IV antibiotics at enrollment or randomization
- •History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
- •Inadequately controlled hypertension
- •Prior history of hypertensive crisis or hypertensive encephalopathy
- •New York Heart Association (NYHA) Class II or greater CHF
- •History of myocardial infarction or unstable angina within 12 months prior to Day 1
- •History of stroke or transient ischemic attack within 12 months prior to Day 1
- •Known central nervous system (CNS) disease except for treated brain metastasis
- •Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1
- •History of hemoptysis within 1 month prior to Day 1
- •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study
- •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
- •History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
- •Serious, non-healing wound, active ulcer, or untreated bone fracture
- •Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
- •Known hypersensitivity to any component of bevacizumab or sunitinib
- •Pregnancy (positive pregnancy test) or lactation
研究组 & 干预措施
1
Experimental
干预措施: bevacizumab (Drug)
1
Experimental
干预措施: sunitinib (Drug)
1
Experimental
干预措施: paclitaxel (Drug)
2
Placebo Comparator
干预措施: bevacizumab (Drug)
2
Placebo Comparator
干预措施: paclitaxel (Drug)
结局指标
主要结局
Best Response
时间窗: From randomization until disease progression/recurrence (by patient)
The best overall response is the best response, per the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.
次要结局
- Serious Adverse Events (SAEs)(30 days following the last administration of study treatment)
- Grade ≥ 3 Adverse Events (AEs)(30 days following the last administration of study treatment)
- Adverse Events Leading to Death(30 days following the last administration of study treatment)
- Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction(30 days following the last administration of study treatment)
- Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption(30 days following the last administration of study treatment)
研究者
相似试验
终止
2 期
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)Non-Small Cell Lung CancerNCT00434226Genentech, Inc.56
招募中
2 期
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT06558227Suzhou Zelgen Biopharmaceuticals Co.,Ltd90
Unknown
2 期
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsTriple Negative Breast CancerNCT04502680The First Affiliated Hospital with Nanjing Medical University100
已完成
2 期
SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialMetastatic CancerRectal CancerMetastatic Colorectal CancerColon CancerColorectal CancerCancerNCT00418938Amgen266
已完成
2 期
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic FibrosisCystic FibrosisNCT00079742Genentech, Inc.68